ContributorsPublishersAdvertisers

Md Anderson

beckershospitalreview.com

MD Anderson inks strategic collaboration for CAR-T therapy development

The University of Texas MD Anderson Cancer Center, Invectys and the Cell Therapy Manufacturing Center entered a strategic collaboration last week to develop a "reliable, compliant and scalable" process for human leukocyte antigen CAR-T cell therapy for solid tumors. The collaboration combines Invectys' technology with the cell therapy development and...
TEXAS STATE
YOU MAY ALSO LIKE
Newswise

MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.
HOUSTON, TX

MD Anderson unveils new cancer research center

*Correction: a previous caption stated Dr. Kalluri was a researcher and has been updated to more accurately reflect his role. Ron Speidel was diagnosed with bladder cancer in 2013. By 2015, following chemotherapy and surgery, the cancer had spread to the bone. With conventional treatment options exhausted, Speidel was told...
HOUSTON, TX
Newswise

MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer

Newswise — HOUSTON and SAN DIEGO ― The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture will advance its work within a culture of academic innovation alongside industrial expertise.
HOUSTON, TX
Nature.com

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients' initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age"‰<"‰45 years, body mass index"‰â‰¥"‰25 kg/m2, presence of the TP53 mutation, and elevated LDH"‰>"‰upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P"‰="‰0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
CANCER
Inside Indiana Business

Community Health Forms Partnership with MD Anderson

A leading global cancer center putting more roots down in Indiana. MD Anderson’s partnership with Community Health and how it could be a difference-maker for Hoosiers battling cancer. In the Business of Health, Community MD Anderson Cancer Center Medical Director Dr. Sumeet Bhatia has more on the partnership.
beckershospitalreview.com

MD Anderson, Community Health Network partner on fully integrated cancer program

The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network entered a partnership April 28 to create Community Health Network MD Anderson Cancer Center. Under the new partnership, Community Health Network physicians will have access to MD Anderson experts for peer-to-peer consultations. Eligible patients throughout central Indiana...
INDIANAPOLIS, IN
Newswise

MD Anderson and Community Health Network Announce Partnership to Create Fully Integrated Cancer Program

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership agreement to create Community Health Network MD Anderson Cancer Center. A comprehensive clinical and research cancer program collaboration in central Indiana, Community MD Anderson will provide Hoosier cancer patients greater access to some of the most advanced oncology care.
HOUSTON, TX